All‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes

David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández Ibarburu, Ramandeep Ghuman, Daniel J. Cuthbertson, Gregory Y. H. Lip, Uazman Alam

Open source

DOI: 10.1111/dom.15185
Published: 2023-06-29
Container: Diabetes, Obesity and Metabolism
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/dom.15185,
  title = {All‐cause mortality and cardiovascular outcomes with
                    <scp>sodium‐glucose</scp>
                    Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes},
  author = {David R. Riley and Hani Essa and Philip Austin and Frank Preston and Isatu Kargbo and Gema Hernández Ibarburu and Ramandeep Ghuman and Daniel J. Cuthbertson and Gregory Y. H. Lip and Uazman Alam},
  year = {2023},
  journal = {Diabetes, Obesity and Metabolism},
  doi = {10.1111/dom.15185},
  url = {https://doi.org/10.1111/dom.15185}
}

RIS

TY  - JOUR
TI  - All‐cause mortality and cardiovascular outcomes with
                    <scp>sodium‐glucose</scp>
                    Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
AU  - David R. Riley
AU  - Hani Essa
AU  - Philip Austin
AU  - Frank Preston
AU  - Isatu Kargbo
AU  - Gema Hernández Ibarburu
AU  - Ramandeep Ghuman
AU  - Daniel J. Cuthbertson
AU  - Gregory Y. H. Lip
AU  - Uazman Alam
PY  - 2023
JO  - Diabetes, Obesity and Metabolism
DO  - 10.1111/dom.15185
UR  - https://doi.org/10.1111/dom.15185
ER  -

APA

Riley, D. R., Essa, H., Austin, P., Preston, F., Kargbo, I., Ibarburu, G. H., Ghuman, R., Cuthbertson, D. J., Lip, G. Y. H., & Alam, U. (2023). All‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15185

Source records

crossref · retrieved 2026-09-26T02:08:04.386Z